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Abstract
Vascular endothelial growth factor (VEGF) is an angiogenic and neurotrophic factor,
secreted by endothelial cells, known to impact various physiological and disease processes
from cancer to cardiovascular disease and to be pharmacologically modifiable. We sought
to identify novel loci associated with circulating VEGF levels through a genome-wide asso-
ciation meta-analysis combining data from European-ancestry individuals and using a
dense variant map from 1000 genomes imputation panel. Six discovery cohorts including
13,312 samples were analyzed, followed by in-silico and de-novo replication studies
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including an additional 2,800 individuals. A total of 10 genome-wide significant variants
were identified at 7 loci. Four were novel loci (5q14.3, 10q21.3, 16q24.2 and 18q22.3) and
the leading variants at these loci were rs114694170 (MEF2C, P = 6.79x10-13), rs74506613
(JMJD1C, P = 1.17x10-19), rs4782371 (ZFPM1, P = 1.59x10-9) and rs2639990 (ZADH2, P =
1.72x10-8), respectively. We also identified two new independent variants (rs34528081,
VEGFA, P = 1.52x10-18; rs7043199, VLDLR-AS1, P = 5.12x10-14) at the 3 previously identi-
fied loci and strengthened the evidence for the four previously identified SNPs (rs6921438,
LOC100132354, P = 7.39x10-1467; rs1740073, C6orf223, P = 2.34x10-17; rs6993770,
ZFPM2, P = 2.44x10-60; rs2375981, KCNV2, P = 1.48x10-100). These variants collectively
explained up to 52% of the VEGF phenotypic variance. We explored biological links
between genes in the associated loci using Ingenuity Pathway Analysis that emphasized
their roles in embryonic development and function. Gene set enrichment analysis identified
the ERK5 pathway as enriched in genes containing VEGF associated variants. eQTL analy-
sis showed, in three of the identified regions, variants acting as both cis and trans eQTLs for
multiple genes. Most of these genes, as well as some of those in the associated loci, were
involved in platelet biogenesis and functionality, suggesting the importance of this process
in regulation of VEGF levels. This work also provided new insights into the involvement of
genes implicated in various angiogenesis related pathologies in determining circulating
VEGF levels. The understanding of the molecular mechanisms by which the identified
genes affect circulating VEGF levels could be important in the development of novel VEGF-
related therapies for such diseases.
Author Summary
Vascular Endothelial Growth Factor (VEGF) is a protein with a fundamental role in devel-
opment of vascular system. The protein, produced by many types of cells, is released in the
blood. High levels of VEGF have been observed in different pathological conditions espe-
cially in cancer, cardiovascular, and inflammatory diseases. Therefore, identifying the
genetic factors influencing VEGF levels is important for predicting and treating such
pathologies. The number of genetic variants associated with VEGF levels has been limited.
To identify new loci, we have performed a GenomeWide Association Study meta-analysis
on a sample of more than 16,000 individuals from 10 cohorts, using a high-density genetic
map. This analysis revealed 10 variants associated with VEGF circulating levels, 6 of these
being novel associations. The 10 variants cumulatively explain more than 50% of the vari-
ability of VEGF serum levels. Our analyses have identified genes known to be involved in
angiogenesis related diseases and genes implicated in platelet metabolism, suggesting the
importance of links between this process and VEGF regulation. Overall, these data have
improved our understanding of the genetic variation underlying circulating VEGF levels.
This in turn could guide our response to the challenge posed by various VEGF-related
pathologies.
Introduction
Vascular Endothelial Growth Factor (VEGF) is secreted largely by endothelial cells and plays a
key role in several physiological and pathological conditions. During growth, development,
Novel Loci Associated with Circulating VEGF
PLOSGenetics | DOI:10.1371/journal.pgen.1005874 February 24, 2016 2 / 23
MC. The Family Heart Study (FHS) work was
supported by the National Heart, Lung, and Blood
Institute’s Framingham Heart Study (contract No.
N01-HC-25195) and its contract with Affymetrix, Inc,
for genotyping services (contract No. N02-HL-6 to
4278). A portion of this research utilized the Linux
Cluster for Genetic Analysis funded by the Robert
Dawson Evans Endowment of the Department of
Medicine at Boston University School of Medicine
and Boston Medical Center. This study was also
supported by grants from the National Heart, Lung,
and Blood Institute (HL-077477, HL093029, HL-K24–
04334), the National Institute of Neurological
Disorders and Stroke (NS17950), and the National
Institute of Aging (AG031287, AG08122, U0149505,
AG033193, AG033040, and P30AG013846). The
Ogliastra Genetic Park (OGP) study was supported
by the Italian Ministry of Education, University and
Research (MERIT RBNE08NKH7_007). For the
PIVUS study, the genotyping was performed by the
SNP&SEQ Technology Platform in Uppsala (www.
genotyping.se). The SNP Technology Platform is
supported by Uppsala University, Uppsala University
Hospital and the Swedish Research Council for
Infrastructures. CS and EI were supported by grants
from the Swedish Research Council and the Swedish
Heart-Lung Foundation when working with this article.
The Val Borbera (VB) study was supported by funds
from Compagnia di San Paolo, Torino, Italy;
Fondazione Cariplo, Italy; Telethon Italy; Ministry of
Health, Ricerca Finalizzata 2008 and 2011–2012 and
Public Health Genomics Project 2010. The Sorbs
work was supported by grants from the German
Research Council (SFB- 1052 “Obesity mechanisms”
to Michael Stumvoll, ATand PK), from the German
Diabetes Association (to ATand PK) and from the
DHFD (Diabetes Hilfs- und Forschungsfonds
Deutschland to Michael Stumvoll and PK). IFB
Adiposity Diseases is supported by the Federal
Ministry of Education and Research (BMBF),
Germany, FKZ: 01EO1001. Dr. Inga Prokopenko and
VL were partially funded through the European
Community's Seventh Framework Programme (FP7/
2007-2013), ENGAGE project, grant agreement
HEALTH-F4-2007-201413. The Hypertensive Adults
(HT) adults samples and data used in the present
study are part of the Biological Resources Center
(BRC) “Interactions Gène-Environnement en
Physiopathologie Cardio Vasculaire” IGEPCV) in
Nancy, France. This work was funded through
INSERM and the Collaborative BioIntelligence
Program. The STANISLAS Family study samples and
data used in the present study are part of the
Biological Resources Center (BRC) “Interactions
Gène-Environnement en Physiopathologie Cardio
Vasculaire” IGE-PCV) in Nancy, France. The
STANISLAS Family Study, as part of the BRC, was
and maintenance of the circulatory system, VEGF is the principal pro-angiogenic factor and it
has additionally, a neurotrophic role. High levels of circulating VEGF have been observed in
individuals with various vascular diseases (myocardial infarction [1], stroke [2,3], heart failure
[4], and atherosclerosis [5]), neurodegenerative conditions (age-related cognitive decline [6]
and Alzheimer dementia [7]), immune inflammatory disorders (rheumatoid arthritis [8],
inflammatory bowel disease [9], and Behçet’s disease [10]) and cancers (breast [11,12], uterine
[13], gastrointestinal [14,15], lung [16] and prostate [17]). An increase of VEGF levels has also
been found in patients with diabetes [18] and various reproductive disorders [19–21]. Reduced
circulating VEGF levels have been observed in amyotrophic lateral sclerosis [22] and spinal
bulbar muscular atrophy [23]. Moreover, since VEGF levels are pharmacologically modifiable,
understanding the determinants of circulating VEGF could support efforts directed at risk pre-
diction, prevention and therapy. Circulating VEGF levels are highly heritable [24–27] leading
to a search for specific genetic determinants within the Vascular Endothelial Growth Factor A
(VEGFA) gene [27–29]. Several putative candidate genes were then identified but could not be
consistently replicated [10,30–41]. A genome-wide linkage study of VEGF levels identified the
6p21.1 VEGFA gene region as the main quantitative trait locus determining variation in VEGF
serum levels [27]. Specific variants at this locus were also identified as the strongest associations
in the first genome-wide association study (GWAS) of circulating VEGF levels based on data
from 3 large cohort studies in this consortium, wherein two addition loci, located at 8q23.1,
and 9p24.2 were also identified [42]. We have now conducted a new GWAS meta-analysis
using an extended sample, the largest to date, and a deeper genomic coverage based on imputa-
tion to the 1000 genomes panel to identify additional genetic variants that explain variation in
circulating VEGF concentrations.
Results
Characteristics of study participants
A GWAS meta-analysis of VEGF levels was performed in 16,112 individuals from 10 cohorts
of European ancestry (see Materials and Methods and Section 1 in S1 Text for details): the Age
Gene/Environment Susceptibility Reykjavik Study (AGES), the Cilento study (Cilento), the
Framingham Heart Study (FHS), the Ogliastra Genetic Park (OGP), the Prospective Investiga-
tion of the Vasculature in Uppsala Seniors Study (PIVUS), and the Val Borbera study (VB)
served as discovery cohorts; the Gioi population, the Sorbs population, the STANISLAS Family
Study (SFS) and a sample of hypertensive adults (HT) served as replication cohorts. The char-
acteristics of study participants are shown in Table 1. The mean age of the participants was
54.8 years, ranging from 30.4 years in SFS to 76.2 years in the AGES. The percentage of females
in the overall sample was 54%, ranging from 37% in OGP to 64% in Sorbs. To account for dif-
ferences in age distribution and gender among the studies, both age and sex were subsequently
used as covariates in the association analyses. Across studies, median VEGF levels ranged from
27.0 to 393.6 pg/ml, with the lowest median levels in HT and SFS studies in which VEGF was
measured in plasma rather than serum (see Section 2 in S1 Text for details). This is expected
since VEGF levels are higher in serum than in plasma secondary to VEGF release from platelets
during clot formation [43,44]. Differences in VEGF levels also partly reflect demographic and
assay differences between the cohorts.
Meta-analysis
An overview of the study design is presented in Fig 1. Due to heterogeneity in the distribution
of VEGF levels among the cohorts (Table 1), a sample size-weighted Z-score (rather than an
inverse-variance) method was chosen for the meta-analysis. A discovery GWAS meta-analysis
Novel Loci Associated with Circulating VEGF
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was carried out for 6,705,861 autosomal variants in 13,312 individuals from the six cohorts
described in the “Characteristics of study participants” section (Stage 1). A Quantile-Quantile
plot for the investigated variants revealed many more variants with lower observed p-values
(P) than expected (S1 and S2 Figs).
There were 920 variants in 5 chromosomal regions (6p12.1, 8q23.1, and 9p24.2, which have
been previously described and two novel regions at 5q14.3 and 10q21.3) that reached genome-
wide significance (P<5x10-8) in the discovery sample (S2 Table). To identify independently
associated variants within these 5 genome-wide significant genomic regions, conditional analy-
ses were carried out in the study with the largest number of samples (FHS). This approach was
selected since our use of a Z-score meta-analysis, which does not yield effect size estimates, pre-
cluded the use of aggregate results for conditional analyses. The conditional analyses revealed
10 independent signals (4 previously known and 6 novel variants). These 10 Stage 1 variants
were carried forward to in-silico (Stage 2) and subsequent de-novo (Stage 3) replication.
Further, 57 variants in 13 loci were suggestively associated at 5x10-8<p-value<1x10-5. At
each locus, a single independent signal was identified using a clumping procedure, and the most
strongly associated variant at each of these 13 loci was also tested in the in-silico replication.
Among them, 2 variants reached a genome-wide level of significance in the joint meta-analysis
of discovery and in-silico replication samples and these two were also carried forward for the de-
novo replication. So a total of 12 variants were carried forward to the de novo replication.
Overall, 10 of these 12 variants, 8 of the 10 independent variants identified in Stage 1 and
the 2 variants identified in Stage 2 (combined discovery and in-silico replication), were success-
fully replicated in the Stage 3 meta-analysis of the combined discovery, in-silico, and de-novo
replication samples (Fig 2 and Table 2).
For these variants, an additional inverse variance-weighted meta-analysis was performed as
a secondary analysis on the Stage 3 data, including the discovery and both replication cohorts.
These secondary meta-analysis results, reported in the Table 2, are concordant with our origi-
nal analysis results.
Table 1. Descriptive statistics for participating cohorts at all stages.
Study* Sample size Age†(mean±SD) Women %(n) VEGF(median; 25%-75%)‡ VEGF(min; mean; max) Undetectable % (n) Stage§
AGES 1548 76.16 ± 5.61 51.17 (916) 50.9; 35.3–75.3 0.2; 61.5; 715.6 0.06 (1) 1
Cilento 1115 51.25 ± 19.29 54.98 (613) 382.8; 232.3–591.4 16.6; 447.7; 2046.6 0 (0) 1
FHS 7048 51.50 ± 15.66 54.27(3825) 284.6;161.7–452.1 2.0; 342.5; 2718.0 0 (0) 1
OGP 897 52.82 ± 18.17 36.57 (328) 65.4; 27.9–109.2 20.8; 86.5; 2690.0 20.4 (187) 1
PIVUS 945 70.20 ± 0.17 50.05 (473) 187.4; 106.2–316.1 10.3; 237.6; 1167.9 0 (0) 1
VB 1759 55.08 ± 17.99 56.45 (993) 66.3; 13.4–137.2 2.7; 106.6; 2429.1 23.5 (414) 1
Gioi 470 55.50 ± 20.30 57.45 (270) 393.6; 226.5–585.8 34.3; 434.7; 1268.7 0 (0) 2
Sorbs 659 48.21 ± 16.26 64.04 (422) 49.3; 0–98.4 2.4; 75; 1269.4 27.8 (183) 2
HT 995 55.51 ± 11.12 50.45 (502) 33.3; 20.7–59.0 4.7; 47; 448.3 0 (0) 3
SFS 676 30.45 ± 14.03 49.85 (337) 27.0; 16.7–43.2 9.7; 35.1; 255.1 0 (0) 3
*Study names were abbreviate as Age Gene/Environment Susceptibility Reykjavik Study (AGES), Cilento study (Cilento), Framingham Heart Study
(FHS), Ogliastra Genetic Park (OGP), Prospective Investigation of the Vasculature in Uppsala Seniors Study (PIVUS), Val Borbera (VB), a village
included in the Cilento study (Gioi), Sorbs population (Sorbs), hypertensive adults (HT) and STANISLAS Family Study (SFS) from Biological Resources
Center (BRC) Interactions Gène-Environnement en Physiopathologie CardioVasculaire” (IGE- PCV).
†Age at measured VEGF levels in years.
‡The median and interquartile range were calculated considering the individuals with undetectable levels of VEGF as having 0 pg/ml.
§The analysis stage in which each cohort was used.
doi:10.1371/journal.pgen.1005874.t001
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Forest plots reporting the effects of the 10 replicated variants in all the cohorts and the
cumulative effect in the inverse-variance meta-analysis are shown in the Fig 3.
Among those 10 signals, 4 were located in novel chromosomal regions (5q14.3, 10q21.3,
16q24.2, and 18q22.3) and 6 (2 novel, independent variants and 4 previously known signals)
were located in previously identified chromosomal regions (6p21.1, 8q23.1, and 9p24.2).
VEGF associated signals in novel chromosomal loci
The leading SNP on chromosome 5q14.3 was rs114694170 (P = 6.79x10-13). This new associa-
tion is located in the intronic region of the myocyte enhancer factor 2C (MEF2C) gene. Condi-
tional analyses did not identify additional independent variants in the region.
In the locus on chromosome 10q21.3, the most significantly associated variant was
rs74506613 (proxy rs10761741 used for in-silico replication has r2 of 0.97, P = 1.17x10-19)
located within the intronic region of the jumonji domain containing 1C (JMJD1C) gene. Con-
ditional analyses did not identify any other independent variants in this region.
Two additional loci reached a genome-wide significance level in the meta-analysis of the
combined discovery and replication samples. At the locus on chromosome 16q24.2, the most
significantly associated variant was rs4782371 (P = 1.59x10-09) located within the intronic
Fig 1. Flow chart for VEGFmeta-analysis study design.
doi:10.1371/journal.pgen.1005874.g001
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Fig 2. Regional plots of top 10 replicated variants in the Stage 1. Regional association plots show–log10 p-values for all variants ordered by their
chromosomal position (build37) within regions of the 10 replicated variants. Panel A shows the 5q14.3 locus. Panels B-D show three independent signals on
6p21.1 locus. Panel E shows the 8q23.1 locus. Panels F-G show two independent signals on 9p24.2 locus. Panel H-J show 10q21.1, 16q24.2 and 18q22.3
loci respectively. The variants were color coded by R-square values with the top variant shaped in diamond. The estimated recombination rates (cM/Mb)
were generated by lifting the HapMap Phase II genetic map from build35 to GRCH37 and showed in blue line. The green arrows represent the known genes
in each locus. Red dotted line represents the genome-wide significant level (P = 5x10-8). Plots in the panels B, D and F are truncated at p-value = 10−20.
doi:10.1371/journal.pgen.1005874.g002
Novel Loci Associated with Circulating VEGF
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Fig 3. Forest plots of the 10 replicated variants. Panels A-J. The effect size (Beta) and the 95%
Confidence Interval (CI) in all discovery and replication studies and the cumulative effect in the inverse-
variance meta-analysis are represented for each replicated variant.
doi:10.1371/journal.pgen.1005874.g003
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region of the zinc finger protein, FOG family member 1 (ZFPM1) gene. At chromosome
18q22.3, the leading variant was rs111939830 which along with the second leading variant
rs2639990 (used as proxy for de novo replication for rs111939830, r2 = 0.48, P = 1.72x10-08)
was located in the intronic region of the zinc binding alcohol dehydrogenase domain contain-
ing 2 (ZADH2) gene.
VEGF associated signals at previously identified loci
The most significant variant on chromosome 6p21.1 was rs6921438 (P = 7.39x10-1467), already
identified in the previous GWAS [42]. Two additional independent variants were also identi-
fied at this locus after conditional analyses. One was rs1740073 (P = 2.34x10-17) which was in
LD with rs4416670 reported in the previous GWAS (r2 = 0.15) [42]. Although the LD between
these two SNPs is relatively low, rs4416670 and rs1740073 are in close physical proximity
(3055 base-pair distance) and conditional analysis confirmed that rs1740073 eliminated the
signal of rs4416670 (P = 4.16x10-21; before adjusting for rs1740073, P = 0.727; after adjusting
for rs1740073), hence we believe the two SNPs, rs1740073 and rs4416670, both represent a sin-
gle locus of genetic variation. This rs1740073 SNP is located about 22Kb downstream from
rs6921438 and both are located upstream of the gene C6orf223, which encodes an uncharacter-
ized protein. The other independent variant identified, about 221kb distant from the main sig-
nal rs6921438, was rs34528081 (P = 1.52x10-18), a novel variant, located upstream of the
VEGFA gene and the mitochondrial ribosomal protein S18A (MRPS18A) gene. The values of r2
between the 3 variants at 6p21.1 are extremely low (rs6921438-rs1740073 = 0.01,
rs6921438-rs34528081 = 0.007, rs1740073-rs34528081 = 0.01), suggesting that the 6p21.1
region has 3 independent variants that modulate circulating VEGF levels.
The leading variant identified on chromosome 8q23.1 was rs6993770 (P = 2.44x10-60). This
SNP, located within an intron of the zinc finger protein multitype 2 (ZFPM2) gene, was already
known to be associated with circulating VEGF levels [42].
On chromosome 9p24.2 the most significantly associated SNP was rs2375981 (P = 1.48x10-
100, which is in strong LD with rs10738760 (r2 = 0.81) reported in the previous GWAS [42]).
This variant lies downstream of the very low-density lipoprotein receptor (VLDLR) and
upstream of the potassium voltage-gated channel subfamily V member 2 (KCNV2) genes. One
novel independent signal also found in this region using conditional analyses was rs7043199
(P = 5.12 x10-14) located about 71kb upstream of rs2375981, in the VLDLR-AS1 gene and
upstream of the VLDLR gene. No LD exists between the two variants (r2 = 0.0008). Thus, in the
9p24.2 region, there are 2 independent variants able to influence VEGF levels.
Explained variance
A genetic score was calculated for each individual using information on the 10 VEGF replicated
variants. This genetic score explained 52% of the observed variability in circulating VEGF levels
in FHS. The proportions of variance in circulating VEGF explained by these 10 replicated vari-
ants in PIVUS, Cilento, AGES, VB, HT, and SFS are 48%, 46%, 24%, 24%, 21% and 19%,
respectively. The observed differences in the proportion of variance explained might be due to
heterogeneity in effect sizes of some SNPs related to the trait variability in distribution of
VEGF levels across the cohorts (Table 2). Accordingly, the explained variability is similar in
the cohorts where a similar distribution of VEGF levels was observed (Table 1).
Functional element analysis in associated loci
To identify putative functional elements at the associated loci, ENCODE data related to chro-
matin modifications and hypersensitivity DNAse sites (DHSs) included in HaploReg [45] were
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analyzed. Among the 10 replicated variants and their 126 proxies (r2>0.8), 16 variants were
located in regions reported as DHSs in 5 or more different cell lines. Among these 16, 11 vari-
ants (rs114694170 on chromosome 5p14.3, rs6993770 on chromosome 8q23.1, rs7043199 on
chromosome 9p24.2, 5 proxies of rs74506613 on chromosome 10q21.3 and 3 proxies of
rs4782371 on chromosome 16q24.2) were also located in a promoter and/or enhancer histone
mark. These results suggest a potential functional role of these variants.
Gene expression analysis
A large database assembled by one of the authors (AJD) that included eQTL association results
from 61 studies (detailed Section 3 in S1 Text) was queried for the 10 replicated variants identi-
fied in the GWAS and their 126 proxies (r2>0.8). Eighty-four variants in three loci (1 repli-
cated variant and 83 proxies of two additional replicated variants) were found in the database.
The variant rs6993770 on chromosome 8q23.1 was a trans eQTL for the CXCL5 gene;
rs609303 (proxy of rs111939830) on chromosome 18q22.3 was a cis eQTL for the TSHZ1 gene.
On chromosome 10q21.3 82 proxies for rs74506613 were identified: 2 variants were trans
eQTL for 6 genes (AQP10, CXCL5, GUCY1A3, ITGA2B,MYL9, and NRGN) and 81 were cis
eQTLs for 3 genes (JMJD1C, NRBF2 and REEP3); one variant rs10761779 is both a trans and
cis eQTL. All 84 variants identified as eQTL in this search are listed in S3 Table.
Biological pathway analysis
In order to identify biological pathways involved in the modulation of VEGF protein levels two
pathway analysis approaches were applied. MAGENTA software [46] was applied to the Stage
1 meta-analysis results, to identify the known biological pathways most strongly represented
among all the variants associated with circulating VEGF concentrations (see Materials and
Methods). Overall, 3,216 biological pathways (with at least 10 genes) and 168,932 genes were
examined. This pathway analysis identified 18 biological pathways, 3 molecular functions and
2 cellular components significantly associated with VEGF levels at a nominal Gene Set Enrich-
ment Analysis (GSEA) p-value0.01. Among these, only the ERK5 pathway reached statistical
significance after correction for multiple testing (FDR threshold of 0.05).
The Ingenuity Pathway Analysis software (IPA, www.qiagen.com/ingenuity) was used to
explore functional relationships between genes in the VEGF associated loci. A total of 26 genes
located at and adjacent to the 10 replicated variants were selected as focus genes for IPA analy-
sis (S4 Table). Among them, 17 genes were found to be biologically linked in a unique network
of 70 molecules as shown in Fig 4. The associated functions for this network were organism
development, especially early embryonic and later cardiovascular system development. The
probability that 17 genes would be linked in a randomly designated set of 26 genes using data
from the Global Molecular Network was 1.0x10-42. Thus, it appears extremely unlikely that this
network has been identified purely by chance.
Discussion
In this GWAS meta-analysis of circulating VEGF levels, we identified 10 independent variants
located in 7 chromosomal loci; 4 of those variants had been described in a previous GWAS
[42]. We now describe 6 novel variants, 4 of which were in newly identified chromosomal
regions (5q14.3, 10q21.3, 16q24.2, and 18q22.3) whereas 2 were identified through conditional
analyses at previously described loci (6p21.1 and 9p24.2). These 10 variants explain about 52%
of VEGF phenotypic variance in the largest cohort in this study, with the 6 novel variants
increasing the explained variance by 4% compared to the 48% described by Debette et al. for
the 4 previously identified loci [42]. This increase represents a valuable addition to the
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proportion of variance explained when compared to the results obtained from GWAS of other
complex traits [47–50].
The newly identified regions include many interesting and plausible candidate genes with
angiogenic and neurotrophic roles.
The leading variant on chromosome 5 was located within an intron of theMEF2C gene.
This protein has a demonstrated role in cardiac myogenesis, morphogenesis and in vascular
development.MEFC2 knock out is embryonically lethal due to cardiac and vascular abnormali-
ties.MEFC2 also supports cortical development and variants in this region have been associ-
ated with severe neurodevelopmental problems in humans such as developmental retardation,
cerebral malformations [51,52], stereotypic movements and epilepsy.MEF2C was also reported
to be associated with retinal vascular caliber in the Cohorts for Heart and Ageing Research in
Genomic Epidemiology (CHARGE) consortium [53], which is particularly interesting given
the known role of VEGF in proliferative retinopathy and macular degeneration.MEF2Cmay
be a transmitter of VEGF signaling and has been shown to be regulated by VEGF in-vitro, as a
key mediator [54].
Fig 4. Network generated by IPA using 26 genes in replicated loci. Edges describe the characteristics of relationship between the two nodes. Lines
between two genes denote verified interaction. The shapes of the nodes represent the functional level of the gene product.
doi:10.1371/journal.pgen.1005874.g004
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The leading variant on chromosome 10 was located in an intronic region of JMJD1C, a pro-
tein-coding gene with an intriguing role in many biological processes ranging from platelet and
endothelial cell function to DNA repair [55]. Thyroiditis [56] and fatty liver disease [57] have
been associated with this gene. A GWAS of plasma liver enzymes revealed an association of
rs7923609 (P = 6.0x10-23, G = risk allele) with elevated enzyme levels indicating abnormal liver
function. Interestingly, this SNP also showed an association with VEGF levels in our study
(P = 1.15x10-12) with the G allele associated with higher levels [58]. In a mouse model, it was
noted that VEGF promotes proliferation of hepatocytes through reestablishment of liver sinu-
soids by proliferation of sinusoidal endothelial cells; thus VEGFmay mediate the genetic asso-
ciation observed [59] between JMJD1C variants and hepatic steatosis.
JMJD1C andMEF2C genes were found associated to platelet count and volume in a Euro-
pean ancestry GWAS [49]. Further, a variant (rs7896518, P = 2.93x10-15) located in an intron
of the JMJD1C gene showed an association with platelet counts (P = 2.3x10-12) in an African
American GWAS [60]. In a second European ancestry GWAS of platelet aggregation another
SNP in the same gene, rs10761741, showed an association with epinephrine-induced platelet
aggregation with the T allele being associated with greater aggregation [61]. Interestingly, this
T allele of rs10761741 was also associated with higher circulating VEGF levels (P = 7.10x10-15).
Because both platelets and VEGF play important roles in the development of atherosclerosis
and arterial thrombosis, investigating the intricate relationships among platelet, VEGF, and
JMJD1Cmight identify novel drug targets and biological pathways implicated in atherosclero-
sis and arterial thrombosis.
In a GWAS of serum androgen levels in European men a variant (rs10822184) in JMJD1C
reached genome-wide significance (P = 1.12x10-8) with the C allele being associated with lower
levels [62]. This variant was also associated with higher circulating VEGF levels (P = 4.06x10-
11). Further, in a GWAS of sex hormone-binding globulin, the T allele of a variant in JMJD1C
(rs7910927) was associated with a decrement of sex hormone-binding globulin concentrations
(P = 6.1x10-35) [63]. This T allele was also associated with a decrement of VEGF levels
(P = 1.31x10-12). Sex hormones influence VEGF levels [64] thus suggesting a hormone-depen-
dent VEGF production mediated by JMJD1C.
The leading variant in chromosome 18 was located in an intergenic region downstream of
the ZADH2 gene and upstream of the Teashirt Zinc Finger Homeobox 1 (TSHZ1) gene and a
variant in strong LD with the lead SNP regulates expression of the latter gene. Both genes have
been reported as candidate genes for congenital vertical talus [65]. TSHZ1 has been associated
with increased expression in Juvenile Angiofibroma (JA) [66]. Because VEGF is secreted by JA,
and VEGF contributes to vascularization in JA [67], the investigation of relationships among
TSHZ1, JA, and VEGF might lead to a new therapy for JA.
The top variant in chromosome 16 was located in an intron of the ZFPM1 gene. The
ZFPM1 gene is also known as Friend of GATA1 (FOG1) gene and is related to ZFPM2, which
was identified in our previous meta-analysis [68]. Both proteins are transcription factors that
play a role in the development of the heart and coronary vessels. Further, a mutation in the N-
finger of the GATA1 gene, abrogating the interaction between GATA1 and FOG1, showed asso-
ciations with X-linked macro-thrombocytopenia, non-X-linked thrombocytopenia and dysery-
thropoiesis [69]. It is possible that the observed association between ZFPM1 and serum VEGF
levels was partly driven by variations in platelet counts.
Biological pathway exploration using IPA showed that the Ubiquitin C (UBC) gene directly
interacted with 10 of the focus genes. The encoded protein is a polyubiquitin precursor [70].
This gene has been associated with progressive accumulation of ubiquitinated protein inclu-
sions in neurodegenerative disorders that involve dysfunction of the ubiquitin-dependent pro-
teolytic pathway [71] and with verbal memory performance [72]. The UBC gene might play an
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important role in the association between variants and circulating VEGF serum as either medi-
ator or confounder. However, a direct role for the UBC gene in determining circulating VEGF
levels was not identified and none of the variants within 60kb of the UBC gene were associated
with circulating VEGF level even at a nominally significant level.
Gene set enrichment analysis revealed the ERK5 pathway as significantly enriched for
VEGF associations. ERK5 pathway is involved in multiple processes, such as cell survival, anti-
apoptotic signaling, cell motility, differentiation, and cell proliferation [73,74]. ERK5 is also
involved in the angiogenic process, where it acts as regulator of VEGF expression [75,76].
More recently it has been reported that this molecule is expressed on the platelet surface, and
acts as platelet activator in ischemic conditions, such as after a myocardial infarct [77].
Based on eQTL analysis, we observed that 3 of the replicated variants were themselves, or in
strong LD with, variants acting as cis and/or trans eQTLs on different genes. In particular,
among those identified as trans-regulated genes, there were some very interesting candidates.
The C-X-C motif chemokine 5 (CXCL5) gene was a trans-regulated gene for 3 variants in
two VEGF associated regions (rs6993770 on 8q23.1 and 2 proxies of rs74506613 on 10q21.3).
It encodes a protein that through the binding of the G-protein coupled receptor chemokine
(C-X-C motif) receptor 2, recruits neutrophils [78,79], promotes angiogenesis [80] and is
thought to play a role in cell proliferation, migration, and invasion in different types of cancer
[81–85]. CXCL5 acts by activating several angiogenic signaling pathways, some of which,
including JAK/STAT [86] and Src family kinases [87] pathways, are also activated by VEGF.
Given the involvement of the two genes in the same pathways, it is conceivable that they could
be co-regulated.
The GUCY1A3 gene encodes the alpha-3 subunit of the Soluble Guanylate Cyclase (sGC),
an heterodimeric enzyme that, acting as main receptor of the nitric oxide (NO), catalyzes the
conversion of guanosine-5'-triphosphate (GTP) in 3', 5'-guanosine monophosphate (cGMP)
and pyrophosphate. This NO-sGC-cGMP pathway controls vascular smooth-muscle relaxa-
tion, vascular tone, and vascular remodeling, and is activated by VEGF signaling. Inhibition of
sGC reduces VEGF-induced angiogenesis [88,89]. Moreover, activation of sGC inhibits platelet
activation [90].
The protein encoded by theMYL9 gene is a myosin light chain that regulates muscle con-
traction by modulating the ATPase activity of myosin heads. In platelets,MYL9 is associated
withMYH9, the major nonmuscle myosin expressed in megakaryocytes and platelets. Defects
in theMYH9 gene are responsible of different autosomal dominant disorders characterized by
thrombocytopenia and platelet macrocytosis [91,92]. Moreover, it has been demonstrated that
MYL9 is involved in pro-platelet formation [93]. In megakaryocytic cells,MYL9 expression is
regulated by RUNX1, a major hematopoietic transcription factor whose haplo-deficiency is
associated with familial thrombocytopenia, platelet dysfunction, and predisposition to leuke-
mia [94].
The ITGA2B gene encodes the integrin alpha chain 2b, a subunit of the glycoprotein IIb/
IIIa, and an integrin complex expressed on the platelet surface. On the activated platelets, it
acts as receptor for fibrinogen; this binding induces platelet aggregation, an essential event in
thrombus formation, and permits clot retraction. Defects in the ITGA2B gene cause Glanz-
mann thrombasthenia, an autosomal recessive bleeding disorder characterized by failure of
platelet aggregation and by absent or diminished clot retraction [95]. Moreover, a GWAS on
platelet count revealed a SNP in the ITGA2B gene region associated with platelets count
(rs708382, P = 1.51x10-8) [49]
As for the ZFPM1 and JMJD1C genes, the observed connection between VEGF levels and
GUCY1A3,MYL9 and ITGA2B genes could be due, therefore, to a regulation of the number
and/or the functionality of the circulating platelets. Overall our data suggest that studies
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clarifying whether the relationship between these genes and VEGF levels is mediated by plate-
lets may be helpful to better understand the role of these genes in VEGF regulation.
In conclusion, the identification of novel genes and pathways associated with circulating
VEGF levels could lead to new preventive and therapeutic strategies for a wide variety of dis-
eases in which a pathophysiological role for VEGF has been implicated.
The major strength of this work is that it is the largest GWAS of circulating VEGF to date. A
limitation is that, due to the heterogeneity in VEGF levels among the cohorts, a sample size-
weighted Z-score method was used to perform the GWAS meta-analysis, which has lower
power to detect associations compared to inverse-variance weighted meta-analysis, hence we
may have failed to detect some real associations. Further, our analysis focused mostly on com-
mon and less frequent variants. Therefore, we could not comprehensively assess the effect of
rare variants on VEGF levels. Identifying rare variants in future studies, could contribute to fur-
ther increasing the proportion of variance in circulating VEGF explained. Also, our study was
confined to individuals of European ancestry. The results need to be replicated in other racial
and ethnic groups. Finally, a functional validation of the identified associations is needed.
Materials and Methods
Subjects
Six discovery data sets including 13,312 samples were analyzed in the Stage 1. The participating
discovery studies were the Age Gene/Environment Susceptibility Reykjavik Study (AGES,
n = 1,548), the Cilento study (Cilento, n = 1,115), the Framingham Heart Study (FHS,
n = 7,048), the Ogliastra Genetic Park (OGP, n = 897), the Prospective Investigation of the Vas-
culature in Uppsala Seniors Study (PIVUS, n = 945), and the Val Borbera study (VB,
n = 1,759). Two additional studies, the Gioi population (Gioi, n = 470) and the Sorbs popula-
tion (Sorbs, n = 659) provided data for an in-silico replication (Stage 2). Further a de-novo rep-
lication (Stage 3) was undertaken in the STANISLAS Family Study (SFS, n = 676) and in a
sample of hypertensive adults (HT, n = 995) from the Biological Resources Center (BRC)
IGE-PCV “Interaction Gène-Environment en Physiopathologie Cardio-Vasculaire. The partic-
ipating cohorts are described further in Section 1 in S1 Text. The local institutional ethics
boards for each study approved the study design. Each subject signed an informed consent
before participating to the study. Further details can be found in S5 Table.
Genotyping, imputation and phenotype collection
In the discovery and in-silico replication cohorts, genotyping was performed using various
arrays, and imputation was carried out using the 1000 genome v3 as reference panel in all stud-
ies. Details of pre-imputation quality control parameters, genotyping platforms and imputation
parameters for each study are provided in S1 Table. In all cohorts blood samples were collected
after an overnight fast, and serum/plasma samples were prepared and stored as described in
Section 2 in S1 Text. Serum VEGF levels (plasma VEGF were measured in SFS and HT) were
measured using commercial ELISA assays as detailed in Section 2 in S1 Text. The de-novo gen-
otyping at SFS and HT was undertaken on a competitive allele specific PCR (KASP) chemistry
array and variants were called using a FRET-based genotyping system.
Genome-wide analyses in contributing studies
In each individual study, a natural log-transformation of VEGF levels was applied. To do that,
in a few studies (AGES, OGP, VB, and Sorbs) where some individuals had VEGF levels below
the detection threshold of the assay, half the minimum value of VEGF found in that cohort was
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arbitrarily assigned to each such participant [96]. The transformed trait, adjusted for age, sex
and additional study-specific covariates (e.g. principal components associated with VEGF lev-
els, study center for multi-site studies), was related to the variant dosages using a linear regres-
sion. Studies with familial correlation used linear mixed effect models to account for familial
relatedness. Detailed information about the software used in each cohort is reported in the S1
Table. An additive genetic model with 1 degree of freedom was applied. Study specific results
of genome-wide per-variant associations underwent additional quality control prior to meta-
analysis. Checking of file formatting, data plausibility, and distributions of test statistics and
quality measurements was facilitated by the gwasqc function of the GWAtoolbox package
v1.0.0 in R [97]. Prior to the meta-analysis, variants with low minor allele frequency (<1%)
and poor imputation quality (r2< 0.4) were removed.
Meta-analysis of GWAS
Meta-analysis was performed in METAL using an effective sample size weighted Z-score
method [98]. This method was chosen over an inverse-variance meta-analysis because of dif-
ferent covariate-adjusted mean values and standard deviations in VEGF levels among studies.
The results of meta-analysis were adjusted for genomic control inflation factor. To define the
effective sample size, the product of the sample size and the imputation quality for each variant
was calculated in each cohort [99]. The sum of the product of each cohort divided by overall
sample size represents the proportion of the effective sample size for each variant Eq (1).
XC
i¼1 Ni  r
2
i
h i
=13; 312 ¼ Effective sample size ð1Þ
where C is the total number of participating cohorts, i indicates the speciﬁc cohort, N is the
sample size used for the variant association test, and r2 is imputation quality of the variant.
After completing initial quality control checks, 6,705,861 variants, each of which was informa-
tive at an effective sample size of>70%, were included in the meta-analysis (Stage 1). The
genomic control inﬂation factor of the metal analysis was 1.003. All variants having a p-value
less than 5x10-8 were considered to be genome-wide signiﬁcant.
Conditional analysis
To identify all independent associations within the loci reaching genome-wide significance,
conditional analyses were performed in a forward stepwise fashion, examining the most signifi-
cant association and including in successive association models the next most significantly
associated variant (P<5x10-8) in a specific region at each step (referred to as the top variant in
Eq (2)). We repeated this process until no more genome-wide significant associations were
found. The conditional analysis model follows the formula (2).
lnðVEGFÞ ¼ b0 þ b1variant þ
Xn
i¼1 biCovariatesi þ
Xk
j¼1 bjTopvariantj ð2Þ
where n is the number of covariates used in the primary GWAS, k is the number of steps. The
conditional analysis was only performed in FHS because it represents the largest cohort in the
meta-analysis. The ﬁnal conditional analysis model included 10 independent variants with p-
values less than 5x10-8 in FHS.
Replication stages
Genome-wide significant variants identified in the conditional analysis were examined in the
two in-silico replication cohorts and also carried forward to de-novo replication. Furthermore,
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for each suggestive locus (5x10-8<P<1x10-5) the lead variant was also examined in the in-silico
replication sample, and those suggestive variants that reached a genome-wide significant p-
value in a meta-analysis of the discovery and in-silico replication data (Stage 2) were also car-
ried forward to the de-novo replication phase. To check for the presence of other independent
variants in the suggestive regions, a clumping procedure implemented in PLINK [100] was per-
formed. The 1000-genome v3 genotypes were used as reference panel for LD calculation; the
physical threshold for clumping was 1 Mb, and the r2 threshold for clumping was 0.1.
For selected variants that failed de-novo genotyping, a proxy variant having either the high-
est linkage disequilibrium (LD) value, or the variant in the same region with the next lowest p-
value was genotyped instead of the lead variant. We considered as replicated, all variants that
reached a genome-wide significance level in the meta-analysis of the discovery and the in-silico
and de-novo replication samples (Stage 3).
For the replicated variants, an inverse variance-weighted meta-analysis was also performed
as a secondary analysis, including in the analysis all the discovery and replication cohorts.
Explained variance
The variants identified after replication stages were used to estimate, in each cohort, a genetic
score associated with circulating VEGF levels by summing the product of the beta-estimate
and genotype for each variant in a given individual Eq (3).
RiskScore ¼
X10
i¼1 bi  Genotypei ð3Þ
where i is the variant, β is effect size of the variant in the cohort, and genotype is additively
coded genotype of the variant. The proportion of phenotypic variance explained by the variants
incorporated in the score was estimated ﬁtting two linear mixed effect models, in which VEGF
levels were regressed, respectively, on: 1) gender and age (basic model); 2) gender, age, and
genetic risk score (risk score model). The variance explained by the replicated variants was esti-
mated as the difference between the variance explained by the risk score model and that
explained by the basic model. The lmekin function (R package), which uses the genomic kin-
ship matrix to correct for relatedness between individuals, if any, was applied.
DNA functional element analysis
The replicated SNPs and variants in LD with them (r2>0.8) were investigated for the presence
of chromatin histone marks and hypersensitive DNAse elements using data from ENCODE
included in Haploreg_v3 software (http://www.broadinstitute.org/mammals/haploreg/
haploreg_v3.php) [45].
Gene expression analysis
A database of expression Single Nucleotide Polymorphism (eSNP) was created collecting
results from multiple published sources, reported in Section 3 in S1 Text. The eSNP results
from each study were included in the database if they met criteria for statistical thresholds for
association with gene transcript levels as described in the original references. To search for
eQTLs among the associations found in the meta-analysis we queried this database for the rep-
licated variants and their proxies (r2>0.8).
Biological pathway analysis
Two different approaches were used to identify biological pathways influencing VEGF
variability.
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The GSEA-like statistical test implemented in MAGENTA program was used to test the
over-representation of genes containing VEGF-associated variants in a given biological path-
way. To do that, all data of meta-analysis results from Stage 1 were used and the gene-set anno-
tations from the Kyoto Encyclopedia of Genes and Genomes (KEGG), PANTHER,
INGENUITY, Gene Ontology, REACTOME and BIOCARTA databases were applied. Each
gene in the genome was scored by the most significant association p-value among all the SNPs
located within a region from 110 kb upstream to 40 kb downstream of each gene’s transcript
boundaries. Confounding effects on gene association scores were identified and corrected for.
This “normalized best gene score” was used to evaluate the gene enrichment against a null dis-
tribution of 10,000 gene sets of identical set size that are randomly sampled from the genome.
The 95th percentile of all gene scores for the meta-analysis was used as the enrichment cutoff.
Genes within the HLA-region were excluded from analysis due to difficulties in accounting for
gene density and LD patterns and only gene sets with at least 10 genes were included in the
analysis. Significance was determined when an individual pathway reached a false discovery
rate (FDR)<0.05.
The Ingenuity Pathway Analysis software (IPA) was used to explore the functional relation-
ship between genes of interest, selected from candidate regions. For this purpose, a candidate
region was defined as comprising all variants between the first and last variants in a chromo-
somal region that were associated at genome-wide significance with circulating VEGF levels,
either in discovery phase (Stage 1) or the combined discovery and replication meta-analysis
(Stage 3). The genes of interest were chosen including all within 60kb of each of the candidate
regions. A total of 26 genes (listed in the S4 Table) fit this description and served as ‘input’
genes for the pathway analysis. Direct and indirect interactions, a reasonable confidence
(experimentally observed, highly predicted, or moderately predicted) and a maximum size of
70 genes/proteins per network were used as parameters in the analysis.
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